Trial Profile
A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subject with treatment-resistant depression in the course of Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2021
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Celon Pharma
- 05 Oct 2021 Results presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
- 27 Apr 2020 Status changed from active, no longer recruiting to completed.
- 23 Apr 2020 Planned End Date changed from 1 Mar 2020 to 26 Apr 2020.